[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subjective-cognitive-decline-scd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subjective-cognitive-decline-scd":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,57,98,132,157,180,207,234,262,289,313,349,381,410,434,459,490,538,574,605,627,648,670,690,713],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100053544","personalized-brain-health-service-and-dementia-prevention-100053544",false,"NCT07698431","Personalized Brain Health Service and Dementia Prevention","Implementation of a Brain Health Service for Personalized Stratification and Prevention of Dementia Risk: The B-HEALTH Project","B-HEALTH","Inclusion Criteria:\n\n* Participants aged 55 to 85 with subjective cognitive complaints and normal screening test performance at the hospital.\n* Participants must have a minimal educational level for a neuropsychological assessment and a minimal digital literacy for the usage of smartphones, computers and Internet.\n\nExclusion Criteria:\n\n* Objective cognitive impairment.\n* Clinically relevant neurological disorders.\n* Major psychiatric disorders.\n* History of drug\u002Falcohol abuse.\n* Unstable medical conditions that could fully explain cognitive complaints, as determined by the investigator.","ALL","55 Years","85 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study evaluates the feasibility of implementing a Brain Health Service (BHS) to assess and reduce dementia risk in individuals with Subjective Cognitive Decline (SCD). A total of 120 participants will be recruited from the Cognitive Disorders Unit at Hospital del Mar and randomly assigned to either a personalized intervention group or a control group receiving general prevention advice.\n\nThe study will assess individual biological and lifestyle-related risk factors for dementia and use validated tools to estimate each participant's risk profile. Participants in the intervention group will be offered a structured dementia risk communication and counseling process, with the option to receive or decline their individual risk estimate.\n\nThe intervention consists of a 6-month multimodal program combining digital and in-person strategies tailored to each participant's risk level. These strategies include personalized recommendations to improve lifestyle factors such as diet, physical activity, sleep, social engagement, and cognitive stimulation.\n\nThe main objectives are to evaluate the feasibility of delivering this type of service, including recruitment, adherence, and retention; to assess the psychological impact of communicating dementia risk; and to examine changes in lifestyle behaviors and cognitive outcomes over time compared with a control group.\n\nThis study addresses the need for early, personalized prevention strategies for individuals with SCD and may inform broader implementation of preventive BHS.",[29],"Subjective Cognitive Decline (SCD)",[31,32,33,34,35,36,37,38,39,40,41,42,43],"Dementia prevention","Alzheimer's disease","Subjective cognitive decline (SCD)","Dementia risk communication","Brain Health Service","Personalized prevention plan","Multimodal intervention","Lifestyle factors","Risk stratification","eHealth","ptau-217","mHealth","non-pharmacological","NOT_YET_RECRUITING","2026-07-07",{"date":47,"type":48},"2026-07-13","ACTUAL",{"date":50,"type":23},"2026-09-01",{"date":52,"type":23},"2028-08-01",{"name":54,"class":55},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","OTHER",1,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":65,"targetDuration":67,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100609370","inrad-observational-study-100609370","NCT07213700","InRAD Observational Study","The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease","InRAD","Inclusion Criteria:\n\n* Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR\n* Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated),\n* Be attending an InRAD Center,\n* Have provided informed consent for long-term follow-up\n\nExclusion Criteria:\n\n-Any patient or legal representative who is unable or unwilling to provide a signed informed consent form",{"count":66,"type":23},50000,"10 Years","OBSERVATIONAL","The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers.\n\nThe InRAD Registry Observational Study has several aims:\n\n* To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease.\n* To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease.\n* To enable researchers to answer similar research questions and compare results in many different areas of the world.\n\nPeople with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.",[71,72,29,73],"Alzheimer's Disease(AD)","Mild Cognitive Impairment (MCI)","Non-Alzheimer Degenerative Dementia",[75,76,77,78,79,80,81,82,83,84,85,86],"Alzheimer's disease (AD)","Dementia","Observational study","Real-world data (RWD)","International registry","Cognitive decline","Lecanemab","InRAD Registry","InRAD Foundation","Cognitive screening (MoCA, MMSE)","AD-specific therapies","Clinical staging","RECRUITING","2026-07-01",{"date":90,"type":48},"2026-07-02",{"date":92,"type":48},"2026-03-30",{"date":94,"type":23},"2036-01",{"name":96,"class":55},"Stichting International Registry for Alzheimer's Disease and other Dementias Foundation",6,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":18,"minAge":19,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":56},"100622414","autophagy-enhancers-to-reduce-sleep-disturbances-100622414","NCT07383311","Autophagy-Enhancers to Reduce Sleep Disturbances","Autophagy-Enhancers to Reduce Sleep Disturbances: A Combined Approach","SpSleep","Inclusion Criteria (SCD participants):\n\n* Men and women\n* Written consent to participate in the study\n* German at native speaker level\n* Age between 55 and 70 years\n* Subjective Cognitive Decline operationalized as:\n\n  1. Subjectively reported decline in cognitive function (particularly memory) despite objectively normal cognitive performance (e.g., WMS-LM)\n  2. Preservation of functional independence\n  3. No dementia\n\nInclusion Criteria (MCI patients):\n\n* Men and women\n* Written consent to participate in the study\n* German at native speaker level\n* Age between 55 and 70 years\n* Mild cognitive impairment (MCI) operationalized as:\n\n  1. A change in cognitive abilities reported by the patient, relatives or clinic staff (i.e. historical or observed evidence of deterioration over time)\n  2. Objective evidence of memory impairment (at least 1.0 Standard Deviation (SD) below the normal range on the Wechsler Logical Memory Scale (WMS-LM)); other cognitive domains may also be affected (i.e. amnestic MCI and amnestic + MCI)\n  3. Preservation of independence of functional abilities\n  4. No dementia\n\nExclusion Criteria (SCD and MCI participants):\n\n* Patients who are unable to give informed consent\n* Polyamine intake via dietary supplements and\u002For participation in corresponding intervention studies\n* Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)\n* Any condition that impairs clinical or neuropsychological examination procedures\n* Diabetes mellitus\n* Polycystic ovary syndrome\n* Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion\n* Previous stroke\n* Severe untreated medical problems or unstable medical condition\n* Current major depressive episode\n* Psychotic disorder\n* Bipolar disorder\n* Current or previous substance abuse\n* Other neurodegenerative disease, e.g. Parkinson's disease\n* Vascular dementia\n* Alcohol abuse\n* Participation in an interventional study in the last 3 months and during the entire study period\n* Sleep disorders\n* Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)\n* Known intolerances or allergies to wheat germ, gluten or histamine\n\nInclusion criteria (healthy controls):\n\n* Men and women\n* Written consent to participate in the study\n* German at native speaker level\n* Age between 55 and 70 years\n* Subjective cognitive disorders are denied\n\nExclusion criteria (healthy controls):\n\n* Subjects who are not able to give informed consent\n* Polyamine intake via dietary supplements and\u002For participation in corresponding intervention studies\n* Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)\n* Mild cognitive impairment (MCI), defined as described above in the patient inclusion criteria\n* Any condition that interferes with clinical or neuropsychological examination procedures\n* Diabetes mellitus\n* Polycystic ovary syndrome\n* Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion\n* Previous stroke\n* Severe untreated medical problems or unstable medical condition\n* Current major depressive episode\n* Psychotic disorder\n* Bipolar disorder\n* Current or past substance abuse\n* Other neurodegenerative disease, e.g. Parkinson's disease\n* Vascular dementia\n* Alcohol abuse\n* Participation in an interventional study in the last 3 months and during the entire study period\n* Sleep disorders\n* Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)",true,"70 Years",{"count":109,"type":23},76,[26],"This clinical trial investigates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), two populations at increased risk of future cognitive decline and dementia. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline.\n\nSpermidine is a naturally occurring polyamine found in foods such as wheat germ and soybeans. It induces autophagy, a cellular degradation and recycling process essential for neuronal maintenance and function. In animal studies, spermidine has been shown to improve memory performance, reduce neuroinflammation, and support mitochondrial health. Preliminary findings from human trials in individuals with SCD or MCI suggest potential cognitive benefits of spermidine, but results are not unequivocal, and the impact on sleep has not been systematically evaluated.\n\nIn this randomized, double-blind, placebo-controlled trial, 76 participants aged 55 to 70 years with SCD or MCI will receive either spermidine (6 mg\u002Fday) or a placebo for 12 weeks. Sleep will be evaluated using overnight EEG in a controlled laboratory setting, focusing on measures such as slow-wave sleep and sleep spindle activity. Memory performance will be assessed before and after the intervention using standardized neuropsychological testing. Numerical skills will be tested at baseline only to compare SCD and MCI participants with healthy controls.\n\nBlood samples will be collected to quantify metabolic indicators, neurodegeneration-related biomarkers, and autophagy-associated proteins. A control group of 38 cognitively healthy individuals will undergo comparable sleep and cognitive assessments without receiving any supplementation.\n\nThe primary objective of the study is to characterize the impact of spermidine on sleep-dependent memory consolidation and to identify associated biological changes relevant to aging and neurodegeneration. The results may inform the development of non-pharmacological strategies aimed at preserving cognitive function in individuals at risk for dementia.",[113,29],"Mild Cognitive Impairment Due to Alzheimer's Disease",[115,116,117,118,119,120,121,122,123],"Mild Cognitive Impairment","Autophagy","sleep","Spermidine","memory consolidation","electroencephalography","polysomnography","randomized controlled trial","subjective cognitive decline","2026-06-29",{"date":90,"type":48},{"date":127,"type":48},"2025-10-28",{"date":129,"type":23},"2029-05",{"name":131,"class":55},"University Medicine Greifswald",{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":106,"sex":18,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":56},"100585012","increasing-physical-activity-through-social-support-and-stress-resilience-100585012","NCT06896825","Increasing Physical Activity Through Social Support and Stress Resilience","Increasing Physical Activity Through Social Support and Stress Resilience (I-PASS) Among Older Adults Living Alone With SCD to Lower ADRD Risk","I-PASS","Inclusion Criteria:\n\n* Aged 60 years or older\n* Living alone and community dwelling\n* Engaging in 60 minutes or less per week of self-reported moderate-to-vigorous physical activity at screening (based on Exercise Vital Sign Questionnaire)\n* Self-reported decline in cognitive functioning\n* Self-reported ownership of\u002Fwillingness to use a smartphone with an iOS or Android operating system (necessary for participants to track their activity using a wearable activity monitor).\n* Able to read and speak in English. We hope to offer the intervention in Spanish in the future; however, currently, the study materials are only available in English, and participation will require ability to read and respond to study materials.\n\nExclusion Criteria:\n\n* Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a physician's note is provided\n* Resting blood pressure greater than 200\u002F110 mmHG as assessed at the baseline study assessment (unless a physician's note is provided)\n* Plans to relocate out of metropolitan Phoenix, Arizona area in the next 6 months\n* Participation in another physical activity, nutrition or weight loss program at time of screening or at any time during the intervention\n* Individuals with mild cognitive impairment (MCI), as determined by either a self-report of receiving a diagnosis of MCI from a health care provider or as assessed by the Telephone-Montreal Cognitive Assessment (T-MoCA) at the Baseline Session. A score \\\u003C 18 is an exclusion criterion.\n* Individuals with neurodegenerative (e.g., dementia), developmental (e.g., autism), neurologic (e.g., Parkinson's, epilepsy), or major psychiatric (e.g., bipolar, schizophrenia) diagnoses\n* Being previously prescribed one of the 5 approved Alzheimer's medications, including: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), Memantine + Donepezil (Namzaric)\n* Score of 9 or higher on the 15-item Geriatric Depression Scale (GDS) at the Baseline Session \\[scores of 9 and higher are indicative of moderate to severe depression\\]\n* History of stroke\n* Incarcerated individuals (i.e., Prisoners)","60 Years",{"count":142,"type":23},86,[26],"The goal of this clinical trial is to learn the effects of technology enhancements when combined with basic education, goal-setting, and self-monitoring to increase physical activity among older adults living alone, experiencing subjective cognitive decline, and currently engaging minimal physical activity (60 minutes or less of moderate to vigorous physical activity). Further, we will examine key psychosocial mechanisms believed to contribute to successful promotion of physical activity, which include social support and stress resilience.\n\nThe primary questions are to determine whether\n\n* the tech-enhanced condition lead to greater physical activity over time?\n* the tech-enhanced condition lead to social support and stress resilience over time?\n* social support and stress resilience mediate the relationship between the study condition and physical activity?\n\nAll participants will engage in self-monitoring of physical activity, will receive weekly text reminders of their physical activity goals for the week, and will receive basic education about the importance of physical activity, social support, and stress resilience for cognitive, physical, and psychological health. Participants in the tech-enhanced condition will also receive access to a study-specific website and virtual coaching to reinforce the information presented. Researchers will then compare the tech-enhanced condition to the basic education condition to determine the benefits of technology to deliver the intervention materials in order to increase physical activity, social support, and stress resilience.\n\nParticipants will:\n\n* Use a Garmin wearable device to monitor their physical activity\n* Be randomly assigned to a basic education condition or tech-enhanced condition\n* Set achievable goals for weekly physical activity, with incremental increases to achieve 7000 average daily steps by the end of the study\n* Respond to surveys to monitor their social support, stress resilience, quality of life, and depression.\n\nThe sample has several risk factors for Alzheimer's disease and related dementias: low physical activity, social isolation risk via living alone, and subjective cognitive impairment. Therefore, a long-term goal includes the determination of the intervention's effectiveness at increasing physical activity, social support, and stress resilience to reduce risk for developing dementia.",[146,29,147,148],"Healthy","Sedentary Behavior","Social Isolation in Older Adults","2026-06-25",{"date":124,"type":48},{"date":152,"type":48},"2025-06-23",{"date":154,"type":23},"2027-04",{"name":156,"class":55},"Arizona State University",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":106,"sex":18,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":24,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":56},"100623359","high-frequency-stimulation-to-improve-cognition-mobility-and-affect-in-individuals-with-and-without-subjective-cognitive-decline-100623359","NCT07395609","High Frequency Stimulation to Improve Cognition, Mobility, and Affect in Individuals With and Without Subjective Cognitive Decline","Inclusion Criteria:\n\n* Community dwelling men and women 65-89 years old\n* Ability to walk unassisted for 10 min\n* English speaking\n\nAdditional Inclusion Criteria for SCD:\n\n* No evidence of dementia or MCI based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) score within normal limits for age, education, and sex using the NACC Uniform Data Set (UDS) norms8\n* Global Clinic Dementia Rating (CDR) score must be 0 or 0.531\n* Subjective report of cognitive complaints with scores \\>20 on the Cognitive Change Index (CCI-20), a validated scale of subjective cognitive decline6; this scale consists of 20 items that are rated on a 5-point Likert scale, where 1= \"Normal: No change compared to 5 years ago\", 3= \"Mild Problem: Some change compared to 5 years ago) and 5=\"Severe Problem: Much worse compared to 5 years ago\"\n* Family history of dementia\u002Fprobable AD in first degree relative (parents, children, siblings)\n* Normal functional behavior in terms of daily activities, based on the Functional Activities Scale32\n* In line with recommendations of the SCD task force33 an informant must be available for two reasons: a) to provide information about the participant's cognition using the informant version of the CDR and CCI-20, and b) to corroborate normal IADL's on the Functional Activity Questionnaire32 (informant data will be collected via a phone call and linked by code with the participant data).\n\nExclusion Criteria:\n\n* If participants score less than 21 on the Telephone Interview for Cognitive Status (TICS)\n* Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.)\n* Severe visual impairment or corrected visual acuity less than 20\u002F40, which would preclude completion of assessments\n* Inability to undergo MRI brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, certain non-removable body jewelry, or shrapnel containing ferromagnetic metal\n* History of severe stroke\n* Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer)\n* Report of lower extremity pain due to osteoarthritis that significantly limits mobility\n* Diagnosis or treatment for rheumatoid arthritis\n* Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)\n* Unable to communicate because of severe hearing loss or speech disorder\n* Planned surgical procedure or hospitalization in the next 4 months (joint replacement, coronary artery bypass graft, etc.)\n* Severe pulmonary disease, requiring the use of supplemental oxygen\n* Terminal illness, as determined by a physician\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Use of walker or wheelchair","65 Years","89 Years",{"count":166,"type":23},60,[26],"The goal is to determine whether three months of at least three times \u002F week of sensory flicker stimulation improves cognition, mobility, and affect in healthy older adults and older adults with and without Subjective Cognitive Decline (SCD). Investigators will also determine whether the intervention slows cortical thinning and declines in brain functional network segregation and changes in blood biomarkers of Alzheimer's Disease (AD).",[29,170],"Healthy Subjects","2026-06-23",{"date":173,"type":48},"2026-06-26",{"date":175,"type":23},"2026-07",{"date":177,"type":23},"2028-10-31",{"name":179,"class":55},"University of Florida",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":56},"100643450","feasibility-usability-and-acceptability-of-virtual-reality-based-cognitive-and-physical-rehabilitation-in-individuals-with-mild-cognitive-impairment-100643450","NCT07638748","Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment","Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment (VR-MCI)","(VR-MCI)","Inclusion Criteria:\n\n* Clinical diagnosis of MCI (MoCA 18-26) or self-reported subjective cognitive decline (SCD)\n* Capacity to provide informed consent\n* Able to provide own transportation to sessions\n* Speaks and understands English\n* Ambulatory\n\nExclusion Criteria:\n\n* Uncontrolled seizures or epilepsy\n* Severe psychiatric illness or active suicidality\n* Inability to follow instructions or tolerate VR (severe motion sickness)\n* Cognitive impairment as a result of a known cause (e.g., dementia, stroke, Traumatic Brain Injury (TBI), medications, etc.)\n* Any condition that the research team determines would interfere with safe participation","90 Years",{"count":190,"type":23},10,[26],"The purpose of this study is to demonstrate feasibility, usability, and acceptability of VR-based cognitive and physical rehabilitation, evaluate adherence, tolerability, and fidelity to the VR intervention and explore preliminary effectiveness of VR-based rehabilitation on cognitive, physical, and functional outcomes",[115,29],[195,196,197],"Virtual Reality","Cognitive Rehabilitation","Physical Rehabilitation","2026-06-09",{"date":200,"type":48},"2026-06-10",{"date":202,"type":23},"2026-06-12",{"date":204,"type":23},"2026-11-30",{"name":206,"class":55},"The University of Texas Health Science Center, Houston",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":163,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":24,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100626812","study-of-bedroom-environment-sleep-intervention-at-home-for-older-adults-living-alone-with-memory-concerns-100626812","NCT07440498","Study of Bedroom Environment Sleep Intervention at Home for Older Adults Living Alone With Memory Concerns","A Pilot Feasibility Study of Bedroom Environment Sleep Intervention at Home for Older Adults Living Alone With Memory Concerns","Inclusion Criteria:\n\n* Age 65 years and older\n* Living alone in a private residence or independent living setting ≥5 days\u002Fweek\n* Subjective cognitive decline (Subjective Cognitive Decline Questionnaire MyCog \\> 7\\] OR objective mild cognitive impairment (Montreal Cognitive Assessment \\[MoCA\\] scores between 18-25).\n* Preserved Function (Functional Activity Questionnaire \\\u003C 6)\n* Community-dwelling\n* Self-reported insomnia symptoms\n* Residence in the current home for ≥3 months\n* Expectation to sleep in the designated bedroom on ≥80% of nights during the 8 week protocol\n\nExclusion Criteria:\n\n* Diagnosis of dementia\n* Presence of acute illness or exacerbation of chronic conditions within the past month.\n* Current enrollment in another intervention study",{"count":215,"type":23},40,[26],"This is an eight-week pilot research study designed to test whether simple changes to the bedroom environment along with brief sleep hygiene strategies, can improve sleep in older adults who live alone, have memory concerns, and experience insomnia symptoms. Older adults may be eligible to participate. The intervention will take 8 weeks, which includes 1-2 in-person visits from the research team at the participant's residence (evaluate the bedroom environment, install participant-agreed bedroom changes, deliver target sleep hygiene strategy) and 2 virtual or telephone calls (support environmental and sleep hygiene strategies) over 8 weeks. Sleep and environment data will be collected at screening\u002Fbaseline, mid-intervention (4-week) and post-intervention (8-week)",[29,72,219],"Insomnia",[221,222,122,223,224,117],"insomnia","home-based intervention","environmental sensors","community-dwelling older adults","2026-06-04",{"date":227,"type":48},"2026-06-08",{"date":229,"type":23},"2026-10",{"date":231,"type":23},"2028-06",{"name":233,"class":55},"Johns Hopkins University",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":56},"100611100","phase-2-biomarker-based-trial-of-npc-1-for-alzheimers-pathology-100611100","NCT07236190","Biomarker-based Trial of NPC-1 for Alzheimer's Pathology","Early-phase Biomarker-based Trial of NPC-1 for Alzheimer's Disease Pathology","NPC1-AD","Inclusion Criteria:\n\n1. Age 55 and older, male and female;\n2. Subjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011 criteria;\n3. Clinical Dementia Rating \\\u003C or = to 2 and Mini Mental Status Exam \\> or = to 16;\n4. Modified Hachinski Ischemic Score \\\u003C or = to 4\n5. Geriatric Depression Scale - 15 \\\u003C 6 documenting absence from significant depressive syndromes\n6. Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable \\> or = to 3-months ;\n7. Biomarker evidence of AD pathology: Plasma abeta42\u002F40 ratio \\\u003C or = to 0.12 AND Plasma p-tau217 \\> or = to 0.25 OR Amyloid PET positive (centiloid \\> or = to 20) as part of routine clinical care.\n8. Sufficient vision and hearing to complete all tests\n9. Study partner available with frequent (at least 1 hour\u002Fday or 1 day\u002Fweek) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake\n10. General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study exclusion list)\n\nExclusion Criteria:\n\n1. CDR \\> 2 MMSE \\\u003C 16;\n2. Significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke);\n3. Alcohol or substance abuse according to DSM-IV criteria within the last 2 years\n4. Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria\n5. Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable)\n6. Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)\n7. Hypertension: defined as uncontrolled BP \\> 160\u002F100\n8. Clinical symptomatic orthostatic hypotension\n9. Diabetes mellitus that requires insulin injections\n10. Hachinski ischemic score \\> or = to 4\n11. Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade \\\u003C 3) and non-metastatic skin cancers (melanoma).\n12. Illness that requires \\>1 visit \u002Fmonth to a clinician\n13. Medications and dietary supplements:\n\n    * a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab\n    * b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollment is permitted)\n    * c. CNS active meds that have not been on stable doses for at least 2 months e.g., cimetidine, beta-blockers, and SSRIs\n    * d. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit\n    * e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded\n14. Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator\n15. Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator.\n\nWomen of Child Bearing Potential (WOCBP)\n\nFor the purposes of this study, women of childbearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:\n\n1. 12-months post-menopausal\n2. Post-hysterectomy\u002Fsurgically sterile\n\nIf a female Participant does not meet either of these criteria they will be considered of childbearing potential and will have a serum pregnancy test performed at Screening, Visit 3 (2 months), Visit 6 (5 months), and Visit 10 (8 months).",{"count":215,"type":23},[244],"PHASE2","This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology",[247,72,29],"Alzheimer Disease",[249,250,251,72,252,253,254],"Open Label","Dietary Supplements","Alzheimer's Disease","Intervention","early phase clinical trial","blood based biomarkers",{"date":227,"type":48},{"date":257,"type":48},"2026-04-01",{"date":259,"type":23},"2027-06",{"name":261,"class":55},"Massachusetts General Hospital",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":18,"minAge":270,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":24,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":288},"100614965","personalized-digital-training-for-cognitive-fitness-in-mild-cognitive-impairment-100614965","NCT07286448","Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment","Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment: the COG-FIT Pragmatic Trial","COG-FIT","Inclusion Criteria:\n\n* Diagnosis of Mild Cognitive Impairment (MCI) based on Petersen (1999) and Winblad (2004), or Subjective Cognitive Decline (SCD) according to Jessen (2014)\n* Mini-Mental State Examination (MMSE) \\> 18 and Clinical Dementia Rating (CDR) ≤ 1\n* Age ≥ 50 years\n* Formal education \\> 3 years\n* Signed informed consent\n* Stable neurotropic pharmacological therapy in the past 3 months (if applicable)\n* Preserved mental capacity (i.e., not under legal guardianship or protective supervision)\n* Preserved ability to understand and produce written and spoken Italian\n\nExclusion Criteria:\n\n* Severe sensory or communication impairments\n* Recent participation (\\\u003C 3 months) in cognitive or rehabilitation programs\n* Failure to provide or withdrawal of informed consent\n* History or evidence of central nervous system disorders that may affect cognition and are unrelated to the study (e.g., major stroke, brain tumors, normal pressure hydrocephalus, traumatic brain injury)\n* History or evidence of major psychiatric disorders\n* Presence of medical conditions that may interfere with cognitive function (e.g., renal or hepatic failure, obstructive sleep apnea, hypothyroidism, vitamin B12 deficiency)","50 Years",{"count":272,"type":23},100,[26],"The goal of this clinical trial is to determine whether a home-based digital cognitive-training program called RICORDO can enhance patients' ability to manage their own health and daily life when they have Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) and are 50 years of age or older.\n\nThe main questions it aims to answer are:\n\nDoes using RICORDO for five weeks raise the Patient Activation Measure (PAM) score more than an at-home paper-and-video education program called S.A.M.B.A.?\n\nDoes RICORDO also improve cognition, everyday functioning, quality of life and mood compared with S.A.M.B.A.?\n\nResearchers will compare individuals who train with RICORDO to those who follow S.A.M.B.A. to determine which approach is more effective.\n\nParticipants will be randomly assigned to one of the two groups and complete three 45-minute sessions per week at home for five weeks. They will also visit the clinic at the beginning and end of the program to complete questionnaires and take brief thinking tests.",[72,29],[115,277,196,278,279],"Digital Therapeutics","Patient Activation","Home-Based Intervention","2026-04-28",{"date":282,"type":48},"2026-04-29",{"date":284,"type":48},"2025-11-28",{"date":204,"type":23},{"name":287,"class":55},"Giovanna Zamboni",2,{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":106,"sex":18,"minAge":140,"maxAge":164,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":298,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":56},"100602988","phase-1-face-phase-ii-a-stage-ii-trial-100602988","NCT07130669","FACE Phase II (a Stage II Trial)","A Facial Expression-based Personalization Engine (FPE) for Monitoring and Modulating Real-time Effective Engagement in Cognitive Training in Older Adults at Risk for AD\u002FADRD (CogT FACE Study Phase II)","Inclusion Criteria:\n\n1. English speaking\n2. Aged 60-89\n3. Living in a home, or independent- or assisted-living facility\n4. Adequate visual and hearing acuity\n5. Anti-depressants, antipsychotics, and\u002For anxiolytics have been stable for at least 7 days\n6. Memory medications have been stable for at least 3 months\n7. Absence of neurological\u002Fvascular disorder (For neurological disorders with minor symptoms check with PI on case-by-case basis)\n\nExclusion Criteria:\n\n1. be enrolled in another intervention study aimed at improving cognition\n2. live in nursing home\n3. diagnosed with Multiple Sclerosis, TBI, chronic heart failure, Parkinson's disease, dementia",{"count":297,"type":23},80,[299,244],"PHASE1","How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD\u002FADRD) is understudied. The objective of the R33 study is to test a novel facial expression-based personalization engine (FPE) for monitoring and modulating real-time effective engagement, with an ultimate goal of enhancing long-term adherence in unsupervised cognitive training in older adults at risk for AD\u002FADRD. Here, Effective engagement is defined as the extent to which someone is actively engaged and performing with significant attention and enjoyment while training, addressing a balance between adherence and cognitive gains\u002Fplasticity from the training. Based on previous work, the hypotheses include that (1) mental fatigue revealed in facial expressions will reflect a trainee's degree of effective engagement, which can be modified by modulating task novelty; (2) the proposed FPE will ensure the effective engagement in cognitive training by monitoring trainee facial expressions and modulating training in response, promoting the trainee's long-term adherence to the training and cognitive plasticity. A Stage II intervention efficacy study will be conducted to compare effective engagement and adherence in unsupervised cognitive training between training programs with vs. without FPE in older adults at risk for AD\u002FADRD. The proposed FPE may assist in monitoring and improving effective engagement and adherence in older adults with unsupervised cognitive training. In the current application, FPE in a cognitive training program called speed of processing training will be tested. However, such FPE may be embedded to any computerized cognitive training in future studies to help address adherence related issues.",[302,29,303],"MCI","Mild Behavioral Impairment","2026-04-21",{"date":306,"type":48},"2026-04-24",{"date":308,"type":48},"2025-10-31",{"date":310,"type":23},"2028-08-31",{"name":312,"class":55},"Stanford University",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":140,"maxAge":20,"enrollmentInfo":320,"targetDuration":4,"studyType":24,"phases":321,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":56},"100567542","effects-of-real-vs-soundless-acoustic-stimulation-during-deep-sleep-on-brain-activity-memory-and-blood-biomarkers-in-older-adults-60-85-with-mild-memory-impairment-100567542","NCT06669546","Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment","Preventing Cognitive Decline Using Portable, Non-invasive Sleep Enhancement","Inclusion Criteria:\n\n* Written informed consent\n* Age between 60 and 85 years\n* Cognitive impairment (subjective and\u002For MoCA between 23-26)\n* Native German speakers or comparably fluent\n* Normal or corrected-to-normal vision.\n* Intact hearing\n* A close cohabitant (partner\u002Fsibling) should be present to support participants in using study materials\u002Fdevices.\n\nExclusion Criteria:\n\n* Insomnia assessed by the Regensburg Insomnia Scale (RIS; Crönlein et al., 2013)\n* Restless leg syndrome assessed by questions concerning typical symptoms.\n* Sleep apnoea assessed by the Berlin Questionnaire (BQ; Netzer et al., 1999)\n* Severely irregular sleep patterns assessed by the RIS and the Pittsburgh sleep quality index (PSQI; Buysse et al., 1989)\n* Symptoms of depression (Geriatric Depression Scale (GDS; Yesavage et al., 1982) ≥ 5)\n* History of untreated severe neurological and psychiatric diseases\n* Alcohol or substance abuse\n* Use of medication acting on the central nervous system",{"count":166,"type":23},[26],"This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality. Dementia, a leading cause of death worldwide, is often associated with disturbed sleep, particularly the loss of deep, slow-wave sleep (SWS). SWS is important for memory and clearing waste from the brain. Poor SWS can worsen memory loss and allow harmful waste to build up, which may increase the risk of dementia.\n\nThe investigators are testing whether phase-locked auditory stimulation (PLAS) can improve SWS in people at a mild stage of cognitive impairment. PLAS uses short sounds played at specific moments to strengthen slow-wave brain activity during sleep. The investigators previous laboratory based research has shown that this can improve memory and help with clearing waste from the brain. Now, the investigators want to test this in a real-world setting, over a longer period, which is unfeasible in a laboratory setting.\n\nIn this study, 60 older adults will use home-use devices that deliver either real or sham (soundless) PLAS across two different 4-week periods. Memory will be tested using engaging \"serious games.\" Before and after each experimental period, blood samples will be taken to measure dementia-related markers, and cognitive batteries will be performed. The investigators expect that PLAS will improve sleep, and that this will have a downstream effect on memory and brain clearance, potentially slowing the process of cognitive decline.\n\nIf successful, this could lead to the development of an affordable treatment that helps people maintain brain health and prevent dementia.",[324,247,29,72,325],"Cognitive Decline","Cognitive Impairment, Mild",[327,76,328,329,330,331,332,333,334,335,336,337,338,339],"Sleep","Prevention","Phase-locked auditory stimulation","Blood-based biomarkers","Home","Longitudinal","Electroneurophysiology","EEG","Memory","Cognition","Serious games","Old age","Human","2026-04-02",{"date":342,"type":48},"2026-04-03",{"date":344,"type":48},"2025-02-21",{"date":346,"type":23},"2028-12",{"name":348,"class":55},"University of Bern",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":355,"minAge":356,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":24,"phases":360,"briefSummary":361,"conditions":362,"keywords":368,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":97},"100629994","effect-of-acupuncture-on-psychoneurological-symptom-cluster-in-breast-cancer-survivors-100629994","NCT07481903","Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors","Inclusion Criteria：\n\n1. Female, aged 18-75 years;\n2. Histologically confirmed Stage 0, I, II, or III breast cancer (according to the AJCC 8th edition)；\n3. Completed active treatment (surgery, chemotherapy, and\u002For radiotherapy) at least 1 month prior to study initiation , and are currently receiving endocrine therapy；\n4. Meet at least 2 of the following 6 criteria:\n\n(1)Visual Analogue Scale (VAS) score for pain ≥ 4 (2)Pittsburgh Sleep Quality Index (PSQI) score ≥ 8 (3)Brief Fatigue Inventory-Chinese version (BFI-C) score ≥ 4 (4)Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) score ≥ 8 (5)Hospital Anxiety and Depression Scale-Depression subscale (HADS-D) score ≥ 8 (6)Functional Assessment of Cancer Therapy-Cognitive Function-Perceived Cognitive Impairments (FACT-Cog-PCI) score \\\u003C 60 ; 5.Has signed the informed consent form and voluntarily participates in this study.\n\nExclusion Criteria:\n\n1. History of psychiatric disorders (e.g., bipolar disorder, schizophrenia, substance addiction)\n2. Presence of diseases that may impair cognitive function or interfere with study assessments (e.g., Alzheimer's disease, Parkinson's disease, brain tumors).\n3. Fatigue attributable to a treatable condition (e.g., hypothyroidism).\n4. Severe debilitation or significant organic disease (e.g., heart failure, severe hepatic\u002Frenal insufficiency, severe anemia, uncontrolled infection).\n5. Use of anxiolytics, antidepressants, psychostimulants, or sedative-hypnotics within the past 4 weeks.\n6. Chronic use of corticosteroids.\n7. Prior acupuncture treatment within 3 months, or participation in an acupuncture or drug clinical trial within 6 months.\n8. History of hemorrhagic disease, severe coagulation dysfunction, or current use of anticoagulants (e.g., warfarin).\n9. Implanted cardiac pacemaker.\n10. Pregnancy or breastfeeding.\n11. Concurrent participation in another clinical study.","FEMALE","18 Years","75 Years",{"count":359,"type":23},228,[26],"This clinical trial aims to assess whether electroacupuncture (EA) can alleviate the psychoneurological symptom cluster (including pain, fatigue, insomnia, anxiety, depression and subjective cognitive decline) in breast cancer survivors, and to evaluate the safety of this therapy.\n\nResearchers will conduct a randomized controlled trial of electroacupuncture (EA) as compared to sham electroacupuncture (SA) in breast cancer survivors with the psychoneurological symptom cluster who are currently being treated with endocrine therapy.\n\nParticipants will receive 16 treatments over 8 weeks. The EA group will receive true acupuncture with continuous wave stimulation (2Hz, intensity as tolerated) administered for 30 minutes per session. The SA group will receive sham acupuncture using blunt (non-penetrating) needles that contact the skin without penetration, along with a 30-second transient device activation instead of the 30-minute continuous stimulation.\n\nTreatment outcomes for pain, fatigue, insomnia, anxiety, depression and subjective cognitive function will be assessed. The primary outcome is response rate of the psychoneurological symptom cluster after 8 weeks of treatment. Secondary outcomes include changes from baseline in the scores of each of the six psychoneurological symptoms.",[363,364,219,365,366,367,29],"Psychoneurological Symptom Cluster(Pain, Insomnia, Anxiety, Fatigue, Depression, Subjective Cognitive Decline)","Pain","Anxiety","Fatigue","Depression",[369,370,371],"Psychoneurological Symptom Cluster","Breast Cancer","Acupuncture","2026-03-15",{"date":374,"type":48},"2026-03-19",{"date":376,"type":23},"2026-04",{"date":378,"type":23},"2028-07",{"name":380,"class":55},"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":356,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":409},"100628092","lombard-cohort-of-brain-health-services-100628092","NCT07457138","Lombard Cohort of Brain Health Services","LoBHeS","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Diagnosis of SCD, FCD, or \"well worried\" individuals without objective cognitive impairment\n* Evaluation at one of the Lombardy BHS\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of mild cognitive impairment or dementia at baseline visit\n* Enrollment in another interventional study with an expected effect on cognition\n* Pregnancy or breastfeeding",{"count":389,"type":23},1000,"The goal of this multicenter prospective observational cohort study is to better understand the clinical, neuropsychological, and biological characteristics of individuals attending Brain Health Services (BHS) in the Lombardy region. The study focuses on adults with subjective cognitive decline (SCD), functional cognitive disorder (FCD), or \"well worried\" individuals without objective cognitive impairment.\n\nThe main questions it aims to answer are:\n\n* What clinical, cognitive, and biological differences exist between individuals who are positive versus negative for Alzheimer's disease (AD) plasma biomarkers (p-tau217) at baseline?\n* What factors predict positivity to AD biomarkers at baseline?\n* How does communication of biomarker results (risk disclosure) affect psychological well-being shortly after receiving results?\n* What factors predict longitudinal changes in AD biomarkers over 5 years?\n* Do baseline biomarkers predict the development of mild cognitive impairment (MCI) or dementia during follow-up?\n\nParticipants will:\n\n* Undergo standard clinical evaluation at their local BHS\n* Provide blood samples for plasma biomarker analysis (e.g., p-tau217, GFAP, NfL, ApoE)\n* Undergo neuropsychological testing and cognitive screening\n* Complete questionnaires assessing psychological impact and risk perception (before and after biomarker disclosure)\n* Undergo additional center-specific procedures when clinically indicated (e.g., MRI, lumbar puncture, polysomnography)\n* Be followed annually for 5 years\n\nThe study plans to enroll approximately 1000 participants across multiple BHS in Lombardy and will follow them for a total duration of 7 years. The results will help clarify the role of biomarkers in early cognitive complaints and support the development of preventive strategies within BHS.",[29,392,251,393],"Functional Cognitive Disorder","Brain Health",[395,396,251,392,397,398,399],"Brain Health Services","Subjective Cognitive Decline","pTau-217","GFAP","NfL","2026-03-13",{"date":402,"type":48},"2026-03-17",{"date":404,"type":48},"2026-02-01",{"date":406,"type":23},"2033-02-01",{"name":408,"class":55},"University of Milano Bicocca",5,{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":140,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":24,"phases":418,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":56},"100628573","chinese-classics-recitation-training-in-subjective-cognitive-decline-100628573","NCT07463391","Chinese Classics Recitation Training in Subjective Cognitive Decline","The Effect of Memory Training by Chinese Classics Recitation on Individuals With Subjective Cognitive Decline","Inclusion Criteria:\n\n* Age ≥ 60 years old\n* At least two \"yes\" responses to the following questions are required:\n\n  1. Forgetting where things are placed?\n  2. Unable to recall the names of good friends?\n  3. Unable to follow and recall conversation?\n  4. Subjective memory problems?\n  5. Consider own memory to be worse than others of a similar age?\n\nExclusion Criteria:\n\n* Objective cognitive impairment defined as ≥ 1.5 standard deviations below standardized cognitive testing (e.g., MMSE)\n* Diagnosis of MCI\n* Clinical Dementia Rating (CDR) ≥ 0.5\n* Diagnosis of major depressive disorder\n* Beck Anxiety Inventory score ≥ 16\n* Other medical or neurological conditions that could explain cognitive decline (e.g., vascular dementia, traumatic brain injury)\n* Claustrophobia\n* Contraindications of MRI (e.g., non-MRI-compatible cardiac pacemaker or devices implanted within the past three months)",{"count":166,"type":23},[26],"Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in culturally specific educational contexts.\n\nThis randomized, assessor-blinded, controlled clinical trial will enroll 60 individuals with SCD to evaluate the effects of a six-month structured Chinese Classics recitation training program. Participants will be randomly assigned to either an intervention group or a non-active control group. Assessments will be conducted at baseline, immediately post-intervention, and during annual follow-up.\n\nMultimodal evaluations will include neuropsychological testing, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), blood biomarker profiling, gut microbiota analysis, and fecal metabolomics. The study aims to examine clinical outcomes and explore potential neurobiological and systemic correlates associated with culturally adapted cognitive training.",[29,396],[123,422,423,424,122],"memory training","Chinese Classics","recitation","2026-03-05",{"date":427,"type":48},"2026-03-11",{"date":429,"type":23},"2026-08-01",{"date":431,"type":23},"2032-12-31",{"name":433,"class":55},"China Medical University Hospital",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":18,"minAge":270,"maxAge":357,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":441,"briefSummary":442,"conditions":443,"keywords":445,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":56},"100627231","physiological-effect-of-non-invasive-photobiomodulation-on-cognition-and-mood-in-older-adults-with-subjective-cognitive-impairment-100627231","NCT07445945","Physiological Effect of Non-invasive Photobiomodulation on Cognition and Mood in Older Adults With Subjective Cognitive Impairment","Inclusion Criteria:\n\n* Affirmative responses to two questions on a self-report questionnaire: \"Do you feel your memory is becoming worse?\" \"If so, are you concerned?\"\n\nExclusion Criteria:\n\n* Presence of clinically diagnosed dementia, mild cognitive impairment, depression, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorder(s), schizophrenia, or other psychiatric disorders.\n* History of a manic, hypomanic, or mixed depressive episode.\n* Treatment with electroconvulsive therapy, intravenous and\u002For intranasal ketamine in the 6-weeks prior to study enrolment.\n* History of substance-use disorder in the past 12 months.\n* Presence of current alcohol-use disorder.\n* A positive urine toxicology screen for non-prescribed substance use.\n* A positive pregnancy test at screening.\n* A history of major medical or neurological illness.\n* A history of traumatic brain injury, stroke, seizures, or previous brain surgery.\n* Current use of anti-coagulants.\n* Contraindications to magnetic resonance imaging (MRI) scanning.\n* Being currently involved in other intervention studies.",{"count":297,"type":23},[26],"Subjective cognitive impairment (SCI) is a non-clinical condition manifesting as a self-reported decline in cognitive function without objective clinical evidence, and is prevalent among older adults and strongly associated with declining mood. This study explores the potential of photobiomodulation (PBM) as a therapeutic intervention for SCI. PBM, using near-infrared light, is a non-invasive neuromodulation approach that has shown promise in improving neuronal function, blood flow, and reducing inflammation in both healthy adults and patients with neurological conditions, including dementia and depression. This study proposes investigating the potential of forehead (tPBM), intranasal (iPBM) and vagal (vPBM) PBM to enhance mood and cognitive function in individuals with SCI as a proof of concept for the future use of PBM as therapy for cognitive decline in general.\n\nThis study will recruit approximately 80 participants with SCI for the study, and the total expected duration of the participant\\'s participation in the study is 5 weeks. The active and sham Neuro 5T device consisting of a headset with a built-in controller, nasal and neck applicators will be used. The nasal and neck applicators each contains a single LED and will be placed into the nostril or neck and secured into place. The headset contains multiple LEDs in a wearable applicator and may be adjusted. The Neuro 5T also contains telemetry features to allow documentation of patient usage of the device. LEDs are semiconductor electronic components that emit light. Participants will be given PBM devices for in-home usage, 2 times a day, 7 days a week, for 5 weeks. Participants will undergo EEG, MRI, cognitive and nasal microbiome assessments before and after the 5-week period.",[29,444],"Subjective Cognitive Impairment",[446,447,448,449,450],"Photobiomodulation","Light Therapy","Electroencephalography","MRI","Neuromodulation","2026-02-25",{"date":453,"type":48},"2026-03-03",{"date":455,"type":23},"2026-06",{"date":378,"type":23},{"name":458,"class":55},"Baycrest",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":356,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":469,"conditions":470,"keywords":475,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":56},"100623863","the-signature-of-alzheimers-disease-in-subjective-cognitive-decline-100623863","NCT07402161","The Signature of Alzheimer's Disease in Subjective Cognitive Decline","Unraveling the SIGNature of ALzheimer's Disease: Integrating Multimodal Biomarkers Through Machine Learning","SIGN-AL","Inclusion Criteria:\n\n* Clinical diagnosis of SCD according to the SCD-I criteria;\n* Mini-Mental State Examination (MMSE) score greater than 24, adjusted for age and education level;\n* Normal functioning on the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales.\n\nExclusion Criteria:\n\n* History of head trauma;\n* Current neurological and\u002For systemic diseases;\n* Symptoms of psychosis, major depression, or substance use disorder.",{"count":468,"type":23},250,"This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging disease-modifying therapies (DMTs). Current biomarkers, such as brain MRI, PET scans, and cerebrospinal fluid (CSF) markers, are highly accurate but costly, invasive, and not widely accessible.\n\nThe study aims to provide cost-effective, scalable tools for early identification of individuals at risk, enabling personalized assessment and timely DMT administration.\n\nObjectives:\n\n* Evaluate the accuracy of innovative, easily accessible biomarkers in predicting biologically confirmed AD.\n* Assess the predictive utility of previously studied methods for SCD patients.\n* Explore new approaches, including automated speech analysis, to identify cognitive decline.\n* Evaluate genetic contributions to AD risk.\n* Integrate data from these various modalities using machine learning to create a predictive model for AD in SCD patients.\n\nStudy Design:\n\nThis is a multicenter, longitudinal, low-intervention study conducted at IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy (UO1) and the Center for Research and Innovation in Dementia, Careggi Hospital, Florence, Italy (UO2). Eligible participants are adults with SCD, intact daily functioning, and Mini-Mental State Examination (MMSE) scores \\>24. Exclusion criteria include neurological or systemic diseases, major psychiatric disorders, substance use, or prior head injury.\n\nParticipants undergo:\n\n* Detailed medical and family history collection.\n* Comprehensive neuropsychological, personality, and independence in daily activities assessment\n* EEG recording in resting state.\n* Blood sampling for plasma biomarkers (Aβ42, Aβ40, p-tau181, p-tau217, t-tau, NfL, GFAP).\n* CSF biomarker analysis (Aβ42, Aβ40, p-tau, t-tau).\n* Genetic analysis of AD-related genes (PSEN1, PSEN2, APOE, TREM2, ABCA7, BDNF, HTT).\n* Speech recording and analysis using standardized tasks to extract features for automated evaluation.\n\nThe study expects to create a machine learning-based predictive model combining biomarker, neuropsychological, EEG, speech, and genetic data to improve early detection and guide personalized patient care.\n\nProcedures:\n\n* Neuropsychological evaluations occur at baseline and two-year follow-up.\n* Language recordings are conducted in controlled settings using standardized picture description tasks.\n* EEG is recorded using 21-channel systems.\n* Blood and CSF samples are collected, processed, and stored at -80°C for subsequent analysis at respective institutional laboratories.\n* Plasma biomarkers are analyzed with Simoa technology; CSF biomarkers are analyzed using chemiluminescent enzyme immunoassay (CLEIA).\n* Genetic analyses employ PCR, high-resolution melting analysis (HRMA), sequencing, and capillary electrophoresis as appropriate for specific genes or polymorphisms.\n\nThe study expects to create a machine learning-based predictive model combining biomarker, neuropsychological, EEG, speech, and genetic data to improve early detection and guide personalized patient care.",[29,471,444,472,473,474],"Subjective Cognitive Complaints (SCCs)","Subjective Cognitive Concerns","Subjective Memory Complaint","Subjective Memory Decline",[476,477,334,478,479,480],"Alzheimer","Neuropsychology","Machine Learning","Biomarkers","Speech","2026-02-03",{"date":483,"type":48},"2026-02-11",{"date":485,"type":48},"2025-10-01",{"date":487,"type":23},"2028-03-01",{"name":489,"class":55},"IRCCS Policlinico S. Donato",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":106,"sex":18,"minAge":19,"maxAge":357,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":500,"briefSummary":501,"conditions":502,"keywords":503,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":537},"100621862","lethe-at-a-personalized-multidomain-lifestyle-intervention-for-individuals-at-increased-risk-of-memory-impairment-100621862","NCT07376135","LETHE-AT: a Personalized Multidomain Lifestyle Intervention for Individuals at Increased Risk of Memory Impairment.","Digitally Supported Lifestyle Programme to Promote Brain Health Among Older Adults - the LETHE-AT Randomised-controlled, Multicentre Pilot Trial","LETHE-AT","Inclusion Criteria:\n\n* Age between 55 and 75 years at the time of screening.\n* Fluency in German.\n* All participants must be able and willing to provide written informed consent form (ICF) prior to any study-related procedures.\n* Ownership of a compatible Android smartphone, or willingness and capability to use a study-provided Android smartphone for the duration of the study.\n* Subjective cognitive decline and\u002For a positive first-degree family history of dementia.\n* Willingness to make meaningful changes in at least three of six lifestyle domains: dietary counselling, physical activity, cognitive training, vascular risk management, social interaction, and sleep and relaxation.\n* Cognitive performance at or slightly below age expectations, defined as an m-TICS (modified Telephone Interview for Cognitive Status) score ≥ 37\u002F50, and a Montreal Cognitive Assessment (MoCA) ≥ 26\u002F30.\n\nExclusion Criteria:\n\n* Diagnosed or suspected dementia or substantial cognitive impairment, defined as an m-TICS score ≤ 36 or MoCA \\\u003C 26, or current or previous use of Alzheimer´s disease or other dementia medication.\n* Significant neurological disease, including but not limited to Parkinson´s disease, Huntington´s disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural haematoma, multiple sclerosis, or a history of significant head trauma with persistent neurological sequelae or known structural brain abnormalities.\n* Diminished decision-making capacity, inability to provide informed consent, inability to complete study assessments, or any condition preventing effective cooperation, as determined by clinical judgement.\n* Severe impairment of vision, hearing, or communication abilities that would preclude participation in study procedure.\n* Any medical or psychiatric condition affecting safe engagement, including but not limited to active malignancy, major depressive disorder, symptomatic cardiovascular disease, or revascularisation procedures within the past year.\n* Current participation in another interventional trial, unless the study team determines this does not interfere with participation in the LETHE-AT.",{"count":499,"type":23},300,[26],"The goal of this clinical trial is to learn whether a hybrid multidomain lifestyle program can prevent cognitive decline and reduce dementia risk in community-dwelling adults in mid- to late life who are at increased risk of Alzheimer´s disease or related dementias but do not yet have significant cognitive impairment.\n\nThe main question the study aims to answer are:\n\n* Whether the structured hybrid multidomain lifestyle intervention is feasible (e.g., adherence and retention rate), and how well the digital components are accepted and implemented in the intervention group.\n* Does the intervention reduces the overall burden of modifiable dementia risk factors and improves global cognitive performance compared with usual care.\n\nResearchers will compare participants assigned to the tailored hybrid multidomain lifestyle intervention group with those in a self-guided multimodal lifestyle advice group.\n\nParticipants assigned to the intervention group will receive a plan adjusted to their individual dementia risk profile. A physician trained in motivational interviewing will review their progress continuously.\n\nThe self-guided multimodal lifestyle advice group will receive rigid but comprehensible lifestyle health advice with reduced access to digital support tools.\n\nParticipants will:\n\n* Complete an initial risk assessment that uses machine-learning triage to identify and prioritize their most important modifiable dementia risk factors.\n* Receive personalized recommendations for gradual lifestyle change, including physical activity, nutrition, cognitive training, other dementia risk-factor management (e.g. hearing impairment), stress \\& sleep management, and social activities.\n* Use a smartphone and smartwatch to passively collect digital biomarkers and to complete questionnaires at regular intervals, so that physicians trained in motivational interviewing can adapt goals through shared decision making.\n* Use a study app as the central access point for the program, including educational content, progress tracking, and gamified challenges with social comparison and incentives.",[72,29],[504,505,506,507,508,123,509,510,511,512,513,514,122,515,516,117,517,518,519,520,521,247,522,523,524,525,526,527,42,40],"dementia prevention","brain health","multidomain lifestyle intervention","Austria","multicenter","physical activity","cognitive training","wearable","smartwatch","App","risk reduction","hybrid digital","dietary counselling","stress management","ANU-ADRI","LIBRA2","Neuropsychological Test Battery (NTB)","telemedicine","Cognition Disorders","mild cognitive impairment","multimodal intervention","multicomponent intervention","motivational interviewing","health coaching","2026-01-21",{"date":530,"type":48},"2026-01-29",{"date":532,"type":23},"2026-01-08",{"date":534,"type":23},"2027-11-01",{"name":536,"class":55},"Medical University of Vienna",3,{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":106,"sex":18,"minAge":270,"maxAge":188,"enrollmentInfo":546,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":548,"conditions":549,"keywords":556,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":573},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure",{"count":547,"type":23},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[76,72,444,550,551,552,553,554,555,29],"Parkinson's Disease (PD)","Lewy Body Disease(LBD)","Mixed Dementia","Frontotemporal Dementia (FTD)","Alzheimer Disease (AD)","Cognitively Unimpaired",[557,76,251,558,559,560,561,449,562,563],"Observational","Parkinson's Disease","Biosample","Genetics","Neuropsychological","Microbiome","Plasma","2026-01-15",{"date":566,"type":48},"2026-01-20",{"date":568,"type":48},"2016-06",{"date":570,"type":23},"2029-12",{"name":572,"class":55},"McGill University",19,{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":583,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":56},"100615165","positive-psychology-for-early-cognitive-decline-effects-on-cognitive-and-brain-function-100615165","NCT07289061","Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function","Application of Positive Psychology Interventions in Individuals With Early-stage Cognitive Decline Related to Dementia: Their Impact on Cognitive and Brain Functioning","Inclusion Criteria\n\n-Documented diagnosis of Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) according to clinical evaluation and site standard criteria.\n\nExclusion Criteria\n\n* Diagnosis of dementia (major neurocognitive disorder) or other major neurocognitive disorder that is moderate or severe.\n* Major psychiatric disorder currently unstable or untreated (e.g., major depression with psychotic features, bipolar disorder, schizophrenia).\n* Neurological conditions that affect cognition.\n* Uncorrected hearing or vision problems that prevent participation in assessments or online sessions.\n* Concurrent participation in another interventional study targeting cognition or wellbeing during the study period.",{"count":582,"type":23},128,[26],"This randomized study tests whether a new multicomponent Positive Psychology program can improve cognition and wellbeing in older adults at the earliest stages of dementia-related decline.\n\nAbout 128 participants with Subjective Cognitive Decline or Mild Cognitive Impairment will be enrolled. Half will be randomized to the Positive Psychology program and half to Treatment As Usual (TAU).\n\nThe program consists of weekly, small-group online sessions for \\~24 weeks plus brief home practices. All participants (both arms) will complete questionnaires and cognitive tests at baseline, during treatment, post-treatment, and 9-month follow-up.\n\nPrimary question: Do participants receiving the Positive Psychology program show better cognitive and brain-function outcomes than TAU at post-treatment and at 9 months? Secondary question: Are effects larger for SCD than MCI? No medicines are used and risks are minimal. If effective, this scalable, low-cost, non-pharmacological approach could complement usual care for people in very early cognitive decline.",[29,72,586],"Alzheimer Dementia (AD)",[588,589,590,591,592,593,594,595],"positive psychology","non-pharmacological intervention for dementia","character strengths","mindfulness","forgiveness","gratitude","humor","alzheimer's disease","2026-01-06",{"date":598,"type":48},"2026-01-07",{"date":600,"type":48},"2025-12-17",{"date":602,"type":23},"2027-07",{"name":604,"class":55},"Aristotle University Of Thessaloniki",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":612,"targetDuration":4,"studyType":24,"phases":613,"briefSummary":614,"conditions":615,"keywords":616,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":56},"100609279","effect-of-accelerated-neuromodulation-of-anterior-cingulate-cortex-to-enhance-cognition-in-older-adults-with-mild-memory-problems-100609279","NCT07212504","Effect of Accelerated Neuromodulation of Anterior Cingulate Cortex to Enhance Cognition in Older Adults With Mild Memory Problems","NACC-EC","Inclusion Criteria:\n\n* 55 - 85 years of age (on the day of randomization)\n* are male or post-menopausal female\n* have a diagnosis of mild cognitive impairment (MCI) based on Montreal Cognitive Assessment score \\\u003C 26 or where available, results from clinical neuropsychological assessment, OR subjective memory concerns and first degree relative, living or deceased, with a probable or confirmed diagnosis of AD\n* score 24 or higher on the Mini Mental State Examination (MMSE)\n* are willing to provide informed consent\n* are able to follow the treatment schedule\n* are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications)\n* have a satisfactory safety screening questionnaire for TMS\n\nExclusion Criteria:\n\n* have a metal plate in their head(such as an ear implant, implanted brain stimulators, aneurysm clips). Dental devices and implants that are non-magnetic are safe.\n* have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures\n* have a cardiac pacemaker\n* have an implanted medication pump\n* have a central venous line\n* have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia\n* have a history of substance abuse in the last 6 months\n* have a history of stroke or other brain lesions\n* have a personal history of epilepsy\n* have a family history of epilepsy\n* are a pregnant or breast-feeding woman\n* have a history of abnormal MRI of the brain\n* have untreated hypo- or hyper-thyroidism\n* have unstable medical condition(s)\n* have any other known contraindications to TMS\n* are on unstable doses of any psychotropic medication such as antidepressants, antipsychotic, mood stabilizers or memory enhancing medications\n* regularly use benzodiazepines or other hypnotics within 2 weeks of randomization",{"count":5,"type":23},[26],"The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol in combination with cognitive training can improve cognitive abilities in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI). The study will look at whether it is safe and tolerable to use accelerated dTMS to enhance the benefits of cognitive training in older adults, and will also gather early information on the effects of accelerated dTMS on memory and other cognitive abilities.",[72,29],[115,396,617,618],"Transcranial Magnetic Stimulation (TMS)","Intermittent Theta Burst Stimulation","2025-10-27",{"date":127,"type":48},{"date":622,"type":23},"2025-11-15",{"date":624,"type":23},"2027-03-15",{"name":626,"class":55},"Rotman Research Institute at Baycrest",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":18,"minAge":634,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":24,"phases":636,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":56},"100547082","a-feasiblity-study-of-green-activity-program-for-people-living-with-memory-challenges-100547082","NCT06403345","A Feasiblity Study of Green Activity Program for People Living With Memory Challenges","GAP","Inclusion Criteria:\n\n* 45 years or older\n* Has memory challenges or difficulties thinking\n* Have access and ability to respond to the telephone (mobile or landline)\n\nStudy partner\n\n* 18 years or older\n* Speaks Spanish or English\n* Identified by the PLMC as a person they feel comfortable with who they would like to join them in the study. The study partner's participation is based on level of support needed for the PLMC.\n\nOutdoor activity professionals\n\n* 18 years or older\n* at least 1 year experience providing outdoor activities\n\nExclusion Criteria:\n\nParticipants living with memory challenges will be excluded if they do not meet inclusion criteria or if they indicate any of the following on the 2023 Physical Activity Readiness Questionnaire + (PAR-Q+) :\n\n* Heart failure or, difficulty controlling Coronary Artery Disease, Diagnosed Abnormality of Heart Rhythm, or other cardiovascular condition.\n\n  * If they report difficulty controlling CAD, Diagnosed abnormality of heart rhythm they will be excluded.\n  * If they endorse a diagnosis of heart failure, AND report symptoms greater than NYHA Functional Classification Stage I: \"No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath,\" they will be excluded. Research assistants will be trained to ask about these symptoms during usual activities of daily living.\n  * If their doctor has told them not to participate in physical activity due to their heart condition or another medical condition, they will be excluded.\n* Cancer and are in an active cycle of infusion chemotherapy or daily radiation treatments.\n\n  * People with cancer whose treatment regimen does not impact their day to day routines (e.g.-oral chemotherapy agents) may participate. Research assistants will be trained to ask about the impact of cancer and cancer care on day to day activities and physical activity.\n  * If their doctor has told them not to participate in physical activity due to their cancer or cancer treatment or another medical condition, they will be excluded.\n* Experienced a black out, fainted, or lost consciousness as a result of a head injury in the past 12 months.\n* Often experienced signs and symptoms of low blood sugar (hypoglycemia) following exercise and\u002For daily activities.\n* 2 or more hospitalizations in 6 months","45 Years",{"count":215,"type":23},[26],"The purpose of this study is to test the Green Activity Program that was designed with people living with memory challenges and their study partners to see if it can be done and if they enjoy the program. \"Green activities\" are nature activities that the person enjoys and can be done with other people or pets. For example, dog walking, hiking, outdoor yoga, and gardening are all green activities. The purpose of the program is to help people living with memory challenges participate in nature activities they enjoy. The goal of the program is to help people stay active and improve their health and well-being.",[115,247,29],"2025-10-13",{"date":641,"type":48},"2025-10-15",{"date":643,"type":48},"2024-07-17",{"date":645,"type":23},"2026-08-30",{"name":647,"class":55},"Indiana University",{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":106,"sex":18,"minAge":356,"maxAge":655,"enrollmentInfo":656,"targetDuration":4,"studyType":24,"phases":658,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":56},"100596881","sleep-stimulation-to-enhance-waste-clearance-in-the-brain-100596881","NCT07051239","Sleep Stimulation to Enhance Waste Clearance in the Brain","Enhancing Waste Clearance Through Sleep Stimulation","For the positive amyloid load group:\n\n-Participants who meet the criteria of subjective cognitive decline or mild cognitive impairment (Clinical Dementia Rating \\\u003C 2; Mini-Mental State Examination ≥ 21) and brain amyloid-beta (Aβ) accumulation confirmed by CSF or amyloid-PET, the inclusion age range is 55-80 years.\n\nFor healthy groups:\n\n-Inclusion age range is 18-80 years.\n\nInclusion criteria:\n\n* Proficiency in the French language (close to native level) to complete the neuropsychological evaluation and cognitive tests.\n* MRI compatibility: absence of metallic materials in the body (implants, vascular clips, certain types of orthopedic material, etc.), a pacemaker or other types of stimulators, cochlear implants, or any other electronic devices.\n\nExclusion criteria:\n\n* Current or past psychiatric or neurological conditions (except for those directly associated with the patient group).\n* The presence of severe untreated sleep disorders.\n* The presence of irregular sleep-wake cycles (due to shiftwork or extreme chronotype).\n* The presence of moderate depression or high levels of anxiety.\n* Ongoing treatment with psychotropic medications (benzodiazepines, antidepressants).\n* Regular or excessive consumption of alcohol or caffeinated drinks.\n* Consumption of other psychoactive substances known to have an impact on the central nervous system.\n* Insufficient visual or auditory acuity to complete the assessments if uncorrected. Normal hearing is required for sound stimulation to be effective.\n* Claustrophobia that prevents undergoing brain imaging (MRI).\n* Pregnancy or currently breastfeeding","80 Years",{"count":657,"type":23},105,[26],"This study aims to examine whether multi-night closed-loop auditory stimulation (CLAS) during sleep can enhance waste clearance and memory consolidation in healthy adults and older adults with subjective cognitive decline or mild cognitive impairment who exhibit elevated brain amyloid levels identified through prior clinical screening. Specifically, the study investigates whether sleep stimulation increases the clearance of plasma biomarkers related to neurodegeneration, improves the brain's waste clearance system, and supports memory consolidation. Participants will undergo five nights each of CLAS and sham (no stimulation) interventions, with a washout period in between. They will also complete clinical assessments, including MRI scans, blood sample collection, and cognitive testing, and will keep track of subjective sleep quality, sleepiness, mood, and fatigue throughout the interventions.",[146,29,72,554],"2025-07-03",{"date":663,"type":48},"2025-07-09",{"date":665,"type":23},"2025-09",{"date":667,"type":23},"2028-09",{"name":669,"class":55},"Erasme University Hospital",{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":674,"acronym":4,"eligibilityCriteria":675,"healthyVolunteers":106,"sex":18,"minAge":356,"maxAge":4,"enrollmentInfo":676,"targetDuration":4,"studyType":24,"phases":677,"briefSummary":678,"conditions":679,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":56},"100440407","neural-mechanisms-of-cognitive-assessment-and-rehabilitation-for-cognitive-decline-100440407","NCT05014893","Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline","Inclusion Criteria:\n\n* Adults being able to walk at least a block, and\n* Adults with subjective cognitive decline (SCD), or\n* Adults with mild cognitive impairment (MCI), or\n* Adults with normal cognitive function\n\nExclusion Criteria:\n\n* Clinical diagnosis of dementia\n* Adults who cannot follow the protocal",{"count":272,"type":23},[26],"This study investigates the neural mechanisms of cognitive function decline, cognitive assessment methods for subjects with mild cognitive dysfunction (Mild cognitive impairment, MCI, or cognitive decline milder than MCI), and the approaches used to improve and restore cognitive function.",[72,29,680,146],"Aging","2025-05-20",{"date":683,"type":48},"2025-05-22",{"date":685,"type":48},"2021-08-06",{"date":687,"type":23},"2026-12-31",{"name":689,"class":55},"National Research Center for Rehabilitation Technical Aids",{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":694,"acronym":695,"eligibilityCriteria":696,"healthyVolunteers":106,"sex":18,"minAge":697,"maxAge":4,"enrollmentInfo":698,"targetDuration":67,"studyType":68,"phases":4,"briefSummary":700,"conditions":701,"keywords":702,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":537},"100584475","korean-joint-registry-for-alzheimers-treatment-and-diagnostics-joy-alz-100584475","NCT06889818","Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)","JOY-ALZ","Inclusion Criteria:\n\n1. Participants must be 19 years of age or older at the time of informed consent.\n2. Patients who are undergoing medical evaluation for newly approved Alzheimer's disease medications after 2021, patients who have decided to initiate treatment with these medications in consultation with their physician after 2021, or patients who have already started treatment with newly approved Alzheimer's disease medications after 2021.\n3. Patients who have undergone an amyloid PET scan to confirm Alzheimer's disease pathology, or cerebrospinal fluid testing for Aβ42 and ptau181.\n4. Clinical diagnosis of Alzheimer's disease, defined as follows:\n\n\u003C!-- -->\n\n1. \\[Alzheimer's Disease Dementia (ADD)\\] - Must meet the criteria for probable Alzheimer's dementia as defined by the National Institute on Aging and the Alzheimer's Association working groups (NIA-AA).\n\n   * Must exhibit cognitive decline that impairs independent daily living.\n2. \\[Mild Cognitive Impairment (MCI)\\]\n\n   \\- Must meet NIA-AA diagnostic criteria for MCI.\n\n   \\- The subject or informant must report cognitive decline.\n\n   \\- Performance on delayed recall of verbal memory must be more than -1.0 SD below the age- and education-adjusted normative mean, or scores on any one or more tests of executive function, language, visuospatial abilities, or attention must be more than -1.5 SD below the age- and education-adjusted normative mean.\n\n   \\- Clinical Dementia Rating scale (CDR) of 0.5.\n\n   \\- Maintenance of independent daily living ability.\n\n   \\- Not categorized as dementia.\n3. \\[Cognitively Unimpaired (CU)\\]\n\n   \\- Delayed recall of verbal memory must be at or above -1.0 SD versus the age- and education-adjusted normative mean, and all executive function, language, visuospatial abilities, and attention tests must be at or above -1.5 SD versus the age- and education-adjusted normative mean.\n\n   \\- Maintenance of independent daily living ability.\n   * If the subject reports cognitive decline, they will be classified as having Subjective Cognitive Decline (SCD).\n\n     5\\. Patients must be ambulatory (use of mobility aids is acceptable). 6. The subject must provide written informed consent to participate in the study. In the case of dementia patients, additional written consent from a guardian is required.\n\nExclusion Criteria:\n\n1. Presence of significant psychiatric disorders associated with intellectual disability, schizophrenia, major depression, bipolar disorder, delirium, etc.\n2. History of substance abuse or alcohol dependence that required treatment within the past five years.\n3. A current diagnosis of cancer that has not achieved remission within the past five years. However, localized prostate cancer, cervical carcinoma in situ, non-melanoma skin basal cell carcinoma, or squamous cell carcinoma are excluded.\n4. Evidence of severe or unstable physical conditions (e.g., dialysis, severe liver disease).\n5. Visual or auditory impairments that prevent the satisfactory assessment of cognitive function.\n6. Inability to perform MRI due to the presence of metallic substances in the body.\n7. Currently participating in another drug clinical trial.\n8. Currently pregnant or breastfeeding.","19 Years",{"count":699,"type":23},4000,"The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.",[115,76,29,247],[703,81],"Real World Data","2025-03-17",{"date":706,"type":48},"2025-03-21",{"date":708,"type":48},"2025-02-24",{"date":710,"type":23},"2034-12-31",{"name":712,"class":55},"Ewha Womans University Mokdong Hospital",{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":106,"sex":18,"minAge":140,"maxAge":4,"enrollmentInfo":721,"targetDuration":723,"studyType":68,"phases":4,"briefSummary":724,"conditions":725,"keywords":728,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":736,"lastUpdatePostDateStruct":737,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":742,"locationsCount":56},"100570006","italian-adaptation-and-validation-of-functional-and-behavioural-scales-for-subjective-cognitive-decline-mild-cognitive-impairment-and-mild-dementia-100570006","NCT06701630","Italian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia.","Functional and Behavioural Scales Validation in Italian.","ITA-VALI-DEM","Inclusion Criteria:\n\n* Age ≥ 60 years;\n* Availability of an informant\u002Fcaregiver, able to judge their functional abilities.\n\nFor neurologically unimpaired elderly:\n\n\\- Normal performance on the Mini Mental State Examination (Folstein et al. 1975; Foderaro et al., 2022).\n\nFor clinical groups: Conditions consistent with:\n\n* Subjective Cognitive Decline (Jessen et al., 2014)\n* Mild Cognitive Impairment (Winblad et al., 2004)\n* Mild Major Neurocognitive Disorder according (DSM-5-TR, APA, 2022).\n\nExclusion Criteria:\n\n* Refusal or inability to sign informed consent;\n* For the clinical groups: other neurological or psychiatric conditions that may explain the presence of cognitive difficulties.",{"count":722,"type":23},390,"1 Day","The first aim of the observational study is the translation, cross-cultural adaptation and validation of functional and behavioral scales used in the diagnosis of neurodegenerative diseases, for which a formal version in Italian is not available at present. In particular, the study includes the following functional and behavioral scales: the Katz's index (Basic Activities of Daily Living, BADL), the Lawton and Brody's scale (Instrumental Activities of Daily Living, IADL), the Everyday Cognition questionnaire (E-Cog), the Neuropsychiatric Inventory Questionnaire (NPI-Q) for assessing the Behavioral and Psychological Symptoms of Dementia. Furthermore, a modified Italian version of the Functional Activities Questionnaire (FAQ), which integrates and updates the content of the original items (e.g., addressing the use of technologies, M-FAQ) will be used in the validation study.\n\nThe second aim is to evaluate the psychometric properties of the M-FAQ, the ECog, and the NPI-Q in terms of reliability and validity.\n\nThe third aim is to apply a Receiver Operating Characteristic (ROC) curve analysis to identify cut-offs of IADL, M-FAQ and ECOG to discriminate between different clinical groups (i.e., neurologically unimpaired elderly; Subjective Cognitive Decline, SCD; Mild Cognitive Impairment, MCI; mild Alzheimer's Disease, AD).\n\nNeurologically unimpaired elderly participants (over 60 years old) and participants with SCD, MCI, mild AD, and their caregivers\u002Finformants will undergo: i) administration of the translated versions of the scales; ii) administration of a Cognitive Reserve questionnaire. For SCD, MCI and AD participants, data from the clinical neuropsychological evaluation will also be collected, while paper-and-pencil psychometric tests to assess global cognitive functioning (Mini Mental State Examination) and logical-abstract reasoning (Raven's Colored Matrices) will be administered to the neurologically unimpaired participants.",[726,29,72,727],"Neurologically Unimpaired Elderly Participants","Major Neurocognitive Disorder",[729,730,731,732,733,734,735],"BADL and IADL","FAQ scale","ECog","NPI-Q","Italian adaptation","Validation","Functional and behavioral scales","2025-02-11",{"date":738,"type":48},"2025-02-13",{"date":740,"type":48},"2024-11-26",{"date":204,"type":23},{"name":743,"class":55},"Casa di Cura IGEA"]